

# Cohort – Health 2000

<https://www.neurodegenerationresearch.eu/survey/cohort-health-2000/>

## Title of the cohort

Cohort – Health 2000

## Acronym for cohort

H2000

## Name of Principal Investigator

Title Research professor

First name Arpo

Last name Aromaa

## Address of institution where award is held

Institution The National Institute for Health and Welfare

Street Address Mannerheimintie 166

City Helsinki

Postcode 00330

## Country

- Finland

## Website

[www.terveys2000.fi](http://www.terveys2000.fi)

## Contact email

[email protected]

## Funding source

### 1. The cohort includes, or expects to include, incidence of the following conditions

- Alzheimer's disease and other dementias
- Parkinson's disease

### When studies on the above condition(s) are expected to become possible

- Already possible

### 2a. Stated aim of the cohort

The main aim of Health 2000 is to provide an up-to-date comprehensive picture of health and functional ability in the working-aged and aged population by studying the prevalence and determinants of most important health problems and associated need for care, rehabilitation and help.

### 2b. Features distinguishing this cohort from other population cohorts

**3a. i) Number of publications that involve use of cohort to date**

305

**3a. ii) Up to three examples of studies to date (PI, Institution, Title of Study)**

**3b. Publication list/link to where data or publications are accessible (if available)**

<http://www.terveys2000.fi/julkaisut.html#2000>

**3c. Information (i.e. research findings) expected to be gained from the population cohort**

**4a. Study criteria: age range of participants at recruitment**

Age in years from: 18

To ('until death' if applicable): until death

**4b. Study criteria: inclusion criteria**

A nationally representative sample of 10,000 persons has been drawn of the population aged 18 and over. Targets of the study are general health, major chronic conditions, functional ability and limitations, determinants of health, diseases, functional ability and limitations, health needs and service needs and their satisfaction.

**4c. Study criteria: exclusion criteria**

none

**5. Size of the cohort (i.e. number of participants enrolled)**

- 5,001 – 10,000 participants

**6a. Measures used to characterise participants**

?

**6b. Additional measures for participants with a clinical disorder**

**6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)**

- No

**7. Study design**

- Cross sectional survey

**8. Cases matched by**

- Other health assessment (specify) / N/A
- no matching

**9a. Does the study include a specialised subset of control participants**

- No

**9b. If yes, description of specialised subset of control participants**

**10a. i) Data collection start date**

31-01-2000

**10a. ii) Data collection end date**

01-09-2001

**10a iii) Data collection for this study is**

- Data analysis ongoing

**10b. Plans to continue the cohort study beyond the current projected end date**

**11. Data collected**

- Through links to other records or registers (such as dental records, police records etc). Please specify
- morbidity register

**12. System in place to enable re-contact with patients for future studies**

- Yes (participants have given permission to be re-contacted via the PIs to ask if they would participate in further studies)

**13a. Format and availability of data stored in a database**

**Language used:**

**13b. Format and availability of data held as individual records**

**Language used:**

**14a. Are data available to other groups**

Yes

**14b. Access policy/mechanisms for access if data are available to other groups**

- Apply to PI or co-ordinator at resource
- Access Committee mechanism
- Resource has own ethics approval so usually no need for separate external ethics approval

**15. Data sharing policy specified as a condition of use**

- No requirement to make data publicly available

**16a. Are tissues/samples/DNA available to other groups**

Yes

**16b. i) Description of available tissues/samples/DNA**

- Living donors: DNA

**16b. ii) Form available tissues/samples/DNA are supplied in**

- Secondary samples: DNA

**16b. iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data**

Yes

**17. Is information on biological characteristics available to other groups**

- No